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ABSTRACT
Alzheimer’s disease (AD) is the most common form of dementia. It is a
progressive neurodegenerative disease that is characterized by the increased
abundance of amyloid beta (Aβ) plaques, and neurofibrillary tangles composed of
hyperphosphorylated tau. Only a handful of medications have been approved by the
Food and Drug Administration (FDA) since AD's discovery more than 100 years ago.
These drugs only treat the symptoms and are best prescribed during the early stages of
the disease. In addition, the drugs do not restore the cognitive loss. It is critical to
discover a novel drug to treat and prevent this disease. We have chosen to repurpose
tolfenamic acid (TA), a drug approved in Europe and parts of Asia, as a treatment for
taupathies.
Data from our lab have shown that C57BL/6 mice treated with TA have
lowered amyloid precursor protein (APP) and Aβ levels (Adwan et al., 2011). Our lab
found that treating APP transgenic mice (line R1.40) with TA led to improved
cognitive function and working memory assessed by the Morris water maze and Ymaze, respectively, and reductions in Aβ plaque burden (Subaiea et al., 2013; 2015).
The lab has also shown that R1.40 mice treated with TA showed a reduction in total
tau, phospho-tau (p- tau) Ser235, Thr181, and CDK5 levels (Adwan et al., 2014). Sp1
is a common transcription factor of both APP and tau that regulates their gene
expression. Thus, we examined the ability of TA to alter tau and its phosphorylation
levels, and its effects in improving learning and memory profile in an htau transgenic
mouse model. These transgenic mice are hemizygous for the htau gene expressing all
six isoforms of the human microtubule associated protein tau (MAPT),and they are

homozygous knockout for the murine tau. We administered mice a corn oil vehicle or
TA at 5 or 50 mg/kg for 34 consecutive days. Memory and learning were assessed by
MWM and Probe Trial I and II.
The protein was isolated from the cortices of the mice. Total tau, p-tau Ser396
and Thr231 protein levels were measured by Western blot. Administration of TA
showed a decrease in protein levels of both 5 and 50 mg/kg treatment groups in
contrast to the control group. Immunohistochemistry staining for p-tau Thr231 showed
reduced p- tau present in the frontal cortex and striatum. In the MWM, the control
group showed poor spatial learning and memory deficits that were attenuated in both
the 5 and 50 mg/kg TA groups. In addition, both TA treatment groups showed
improved memory retention in Probe Trial I and II compared to the control. These
results show TA as a novel drug for AD as it lowered AD biomarker protein levels and
improved cognitive function within the htau mouse model.
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CHAPTER 1
INTRODUCTION
Alzheimer’s disease (AD) affects over 5 million Americans and it is the sixth
leading cause of death in the US (Alzheimer’s Association, 2015). It is a
neurodegenerative disease and it is the most common form of dementia. Dementia is
characterized by the progressive loss of memory and decline in everyday activities.
Neurons become damaged in demented patients and eventually die, leading to changes
in memory, decision making, and behavior. People with AD often have difficulty
completing familiar tasks and remembering friends and family. Eventually, patients
lose their independence and require family members or friends for care. In 2013, an
estimated 15.5 million caregivers provided 17.7 billion hours of unpaid care to those
with AD, a value estimated at $220 billion. Based on these numbers, the cost of care is
expected to increase to $1.2 trillion in 50 years (Alzheimer’s Association, 2015).
Two pathophysiologic hallmarks of the disease are the excess amount of
amyloid beta (Aβ) plaques from amyloid precursor protein (APP) and neurofibrillary
tangles (NFTs) formed by hyperphosphorylated tau protein. Specificity protein 1 (Sp1)
is a transcription factor associated with AD pathology and it is the common
transcription factor for APP and tau. Tau is a microtubule- associated protein (MAPT)
that binds to tubulin, promoting the assembly and stabilization of microtubules.
Normally, tau is phosphorylated by the main kinases cyclin-dependent kinase 5
(CDK5) and glycogen synthase kinase 3 beta (GSK-3β). When tau becomes
hyperphosphorylated at phosphorylation sites, such as Threonine (Thr) 231 or Serine

1

(Ser) 396, it can no longer bind to the microtubules. As a result, tau begins to
aggregate and first form paired helical filaments (PHF) and then NFT.
The biggest risk factor for developing AD is age (Vinters, 2014). Currently, 1
in 9 Americans over the age of 65 have AD and 1 in 3 people over 85 have the disease
(Alzheimer’s Association, 2015). The risk of developing AD is expected to increase at
an alarming rate over the next 50 years. This is because of the longer life expectancy
and aging baby- boomers will account for 51% of the people diagnosed with AD ages
65 and older (Alzheimer's Association, 2015). Without a cure, the number of people
diagnosed is expected to rise from 5 million to 16 million by 2050 (Alzheimer’s
Association, 2015, Brookmeyer et al., 1998; Nelson et al., 2011).
The costs associated with creating a new drug are on average of one billion
dollars, and require up to 12 years of research and development (Ng, 2011, PhRMA,
2013). Each phase of drug development progresses with risk and has a failure rate of
over 95% (Hartung, 2013). As a result, many compounds or drugs are left abandoned
in the pipeline with the potential to be repurposed. Repurposing a drug involves
studying a pre-existing compound or biologic that is currently in use to treat a disease
and determining if it can be used for the treatment of another disease (Ng, 2011).
Furthermore, it is useful to study a drug that has already been approved and released to
the market. This is because of the pharmacokinetic (PK) and pharmacodynamic (PD)
parameters that have been established, saving research investment.
Since the identification of AD more than 100 years ago no drug has
successfully targeted the pathological features of AD to alleviate and restore memory
and cognition. However, drugs are available to treat symptoms of the disease such as

2

cholinesterase inhibitors (e.g. donepezil) and N-methyl-D-asparate antagonists (e.g.
memantine). Cholinesterase inhibitors prevent the breakdown of acetylcholine (Ach),
a neurotransmitter involved in memory, learning, and thinking. Patients with AD have
lower levels of Ach and thus it is believed to benefit someone with impaired memory
(Fayed et al., 2011). Drugs such as donepezil (Aricept) are best prescribed during the
early stages of AD. However, the approved drugs only delay the worsening of
cognitive deficits for 6- 12 months on average and at least half of the patients do not
respond to them (Alzheimer’s Association, 2015). In addition, the neuronal damage
caused by the disease cannot be reversed by these drugs (Mancuso et al., 2014,
Ozudogru et al., 2012). Another cholinesterase inhibitor (e.g. tacrine) is no longer
prescribed because liver damage was a serious side effect (Qizilbash et al., 2000).
Developing a safe drug that not only targets the symptoms but also reverses the
cognitive deficits is a critical step in fighting AD. Instead of emulating the currently
approved FDA medications which cannot cure the disease, we propose the drug,
tolfenamic acid (TA), possess a unique mechanism of action different from what exists
on the market.
TA is a non-steroidal anti-inflammatory drug (NSAID) currently approved for
the treatment of migraines and rheumatoid arthritis in Europe. TA has been available
for over 35 years and the PK and PD parameters are well cited. Unlike many NSAIDs
that may cause gastric irritation, TA is a well- tolerated and safe drug (Alhava, 1994;
Eskerod, 1994; Hendel, 1994; Isomaki et al., 1984). In addition, long-term studies
reported minimal or no adverse effects with TA in gastrointestinal histology, renal
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function, and liver function (Khwanjai 2012; Sankpal 2013). This makes TA a
superior candidate to repurpose for AD research.
The distinct mechanism of TA targets the transcription factor Sp1, a zincfinger DNA binding protein. It preferentially binds to GC- rich promoter regions and
regulates the expression of housekeeping genes (Beishline and Azizkhan- Clifford,
2014 and Li et al., 2004). Sp1 is also studied in cancer research for its regulation of
genes involved with cell growth, differentiation, apoptosis (Li et al., 2004; Kaczynski
and Urrutia, 2003; Tan and Khachigian 2009). It has been noted that high Sp1 levels
correlates with decreased survival for cancer patients (Li et al., 2004). Multiple cancer
studies have shown TA's ability to inhibit Sp1 levels (Abdelrahim et al., 2006; Basha
et al., 2005, 2011; Colon, 2009; Eslin et al., 2013; Maliakhal et al., 2012; Sankpal et
al., 2013). In fact, when compared to many of the available NSAIDs, TA was able to
significantly decrease Sp1(Abdelrahim et al., 2006). This was a strong indicator to
select TA as a novel mechanism for AD.
Sp1 co-activates the transcription of APP and tau (Christensen et al., 2004;
Docagne et al., 2004, Heicklen-Klein and Ginzburg, 2000). As a result, we have
chosen to study this drug as a modifier of an upstream target for AD. It was shown
that TA crosses the blood brain barrier within mice brains (Subaiea et al., 2011). In a
follow-up study, wild-type C57BL/6 mice were dosed with TA and it was found that
the gene expression of APP was lowered and protein levels of Sp1, APP, and its
product Aβ were reduced relative to controls (Adwan et al., 2011).
Next, the transgenic mouse line (R1.40), hemizygous for the human APP gene,
and SH-SY5Y cell line were used to investigate TA. It was reported that Sp1, APP,
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and Aβ were reduced in both models (Adwan et al., 2013). More evidence was
provided by dosing the same mouse model with TA for 34 days and finding a decrease
in Sp1 and APP protein levels and Aβ, while Sp1 mRNA remained unchanged
(Subaiea et al., 2013). Moreover, cognitive deficits and memory were recovered in
behavioral tests, including the Morris water maze (MWM) and Y-maze.
Since Sp1 regulates the gene expression of both APP and tau, further research
on tau was performed. Dosing R1.40 mice with TA for 34 days showed that tau
mRNA and protein levels were lowered (Adwan et al., 2014). In addition, levels of
phospho- tau (p-tau) at sites Thr 181 and Ser 235 were reduced. Based on the evidence
that TA reduces tau in a human APP mouse model, we chose a new tau transgenic
mouse model (htau) to study the effects of TA and tau proposed in Figure 1. It was
important to select a mouse model that contained the human tau gene with a nonmutated promoter region. htau mice develop tau pathology slower when compared to
some mouse models, which have accelerated tau accumulation and earlier impaired
memory. This way, the human AD pathology is resembled more accurately.
To study whether TA is effective in treating htau mice, total tau, p-tau Thr231
and Ser396 were analyzed by Western blot. In addition, the gene expression of tau was
measured by quantitative polymerase chain reaction (qPCR). Finally, the MWM and
Probe Trial I and II behavior studies were performed to assess improvement in
cognitive function.
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CHAPTER 2
MATERIALS AND METHODS
Animal model
The htau mouse model, strain B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J, was
obtained from Jackson Laboratory (Bar Harbor, ME). The animals are hemizygous for
the human tau gene, expressing all six isoforms of the human tau (3R and 4R). The
transgene contains the coding sequence, intronic regions, and regulatory elements of
the endogenous human promoter region and they are homozygous for the knock-out
murine tau. These mice aggregate paired helical filaments made of insoluble tau as
early as 2 months and hyperphosphorylated tau is detected at 3 months of age.
Visuospatial and learning deficits occur as early as 6 months assessed by the MWM.
Mice were bred in-house in the designated animal facility at the University of Rhode
Island with a 12:12 hour light-dark cycle (light on at 6:00 AM; light off at 6:00 pm).
Food and water were provided ad libitum.

Genotyping of htau mice
Presence or absence of the human tau gene was determined through
genotyping by standard polymerase chain reaction (PCR) using MJ Research
MiniCycler PTC- 150 (Bio-Rad, Hercules, CA). Following the literature, DNA was
isolated from 2 mm mouse tail snips (Turuett et al., 2000). Tail snips were placed in
an Eppendorf tube and 75 µl of 25 mM NaOH/ 0.2 mM EDTA was added and placed
in a thermocycler at 98 oC for 1 h. After, the tail snips were mechanically ground with
a pipette tip and then the temperature was reduced to 15 oC for 30 min. Next, 75 µl of
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40 mM Tris HCl (pH 5.5) was added and centrifuged at 4,000 rpm for 3 min and
supernatants were collected. DNA integrity was checked using NanoDrop 2000
Micro- Volume UV-Vis Spectrophotometer (Thermo Scientific, Wilmington, DE).
All the following reagents in this section were obtained from Invitrogen
(Carlsbad, CA), unless otherwise stated. Standard PCR was used with the following
primers: sense 5'-CGAAGTGATGGAAGATCACG-3' and antisense 5'GTCTTGGTGCATGGTGTAGC-3'. Each reaction consisted of 44 µl Platinum PCR
SuperMix, 2 µl of each primer, 1 µl 10X BlueJuice loading dye, and 1 µl DNA with
the reaction cycle as follows: 95 oC for 2 min, 95 oC for 30 s, 50 oC for 30 s, and 72 oC
for 15 s for 35 cycles. Next, bands were separated on a 2% UltraPure agarose gel
containing ethidium bromide by gel electrophoresis and imaged using Typhoon™
9410 Variable Mode Imager (GE Healthcare, Piscataway, NJ).

Mice exposure to tolfenamic acid (TA)
The previous mouse model used by the lab (APP YAC, line R1.40) showed
TA affected the amyloid and tau pathology. Our lab has shown that TA has the ability
to decrease levels of APP, Aβ, tau, CDK5, β- APP cleaving enzyme 1 (BACE1), and
Sp1 in this mouse model (Adwan et al., 2014; Subaeia et al., 2011, 2013, 2015). In
addition, we have shown that memory and cognitive function were attenuated in these
mice by administering TA.
TA was obtained from Sigma- Aldrich (St. Louis, MO). Since tau begins to
aggregate at 3 months, male and female htau mice from different cohorts, aged 3-4
and 5-8 months, were used to examine TA's ability to lower tau pathology. Each
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cohort was separated into 4 groups by similar age variation and gender and dosed with
TA or corn oil vehicle by oral gavage for 34 consecutive days. On Day 15 of dosing,
behavior studies began and concluded on Day 35 where mice were sacrificed and
brain tissues were collected and stored at -80 oC until further use. Mice (aged 3-4
months) were divided into two control groups as carrier of the human tau (n= 10) and
non-carrier of the human tau (n= 10). The third and fourth groups were given TA at a
low dose of 5 mg/kg (n= 9) or high dose of 50 mg/kg (n= 10). Mice (aged 5-8 months)
followed the same dosing scenario by oral gavage: control carrier (n= 5), control noncarrier (n= 12), and TA at 5 mg/kg (n= 8) or 50 mg/kg (n= 7) The timeline of behavior
studies are shown in Figure 2. Female mice (aged 13 months) were also dosed with 0
(n= 3), 5 mg/kg (n= 3), or 50 mg/kg (n= 4) TA for 34 days for immunohistochemistry.
All experiments were performed in accordance with the standard guidelines and
protocol approved by the University of Rhode Island Institutional Animal Care and
Use Committee with supervision of the university's veterinarian.

Morris water maze
In the hidden version of the MWM, mice had to locate the hidden platform by
learning multiple spatial cues by associating the platform location with the distal
extramaze cues (Gulinello et al., 2009; Laczo et al., 2009; Vorhees and Williams,
2006). The maze apparatus consisted of a white pool (48" diameter, 30" height) filled
with water to a depth of 14". White, non-toxic paint (Crayola, New York City, NY)
was used to make the water opaque. Distinct visual cues were placed along the sides
of the pool for the animals to navigate to the escape platform. A clear Plexiglas
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platform 10 cm2 was submerged 0.5 cm below the surface of the water and
temperature of the water was maintained at 25 + 2 oC during all procedures.
A habituation trial allowed the mice to swim freely for 60 s to acclimate to the
experiment, which commenced on Day 15 of drug administration. Mice received 3
daily training sessions for a total of 8 days. The starting position was randomly
assigned between four possible positions while the platform remained fixed for each
trial. Each animal had a maximum duration of 60 s to swim to find the immersed,
hidden platform. If a mouse failed to locate the platform, it would be guided to sit on
the platform for 30 s. If a mouse was successful, it could sit on the platform for a
maximum of 10 s. Following the completion of 8 training day sessions, probe trials
were performed up to 60 s on Day 24 and Day 34 to assess long-term memory
retention and the mice's preference for the correct quadrant where the hidden platform
was previously located. The swim paths and latencies were videotaped and analyzed
with a computerized video- tracking system (ObjectScan, Clever Sys. Inc., Reston,
VA, USA).

Protein extraction and Western blot analyses
Brain cortices were homogenized with radio-immunoprecipitation assay
(RIPA) lysis buffer (10 mM Tris- HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100,
0.1% sodium dodecyl sulfate, 1 mM ethylenediaminetetraacetic acid, 0.1% protease
inhibitor cocktail, and 10 µl phosphatase inhibitor (Sigma- Aldrich). The homogenates
were centrifuged at 8,000 rpm for 10 min at 4 oC and supernatants were collected.
Protein concentration was determined by Pierce bicinchroninic assay (BCA) kit
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(Thermo Scientific, Waltham, MA). Twenty- forty microgram of total protein were
separated onto 10- 12% polyacrylamide gel at 100 V for 2 hours and then transferred
to polyvinylidiene difluoride (PVDF) membranes (GE- Healthcare). Membranes were
blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline containing
0.5% Tween-20 (TBST) for 1 hour. Membranes were incubated with appropriate
dilution of specific antibody in TBST overnight at 4 oC. The following antibodies
were used: 1: 5,000 dilution of total tau (ab32057, Abcam, Cambridge, MA); 1: 500
Ser396 (PHF13) (9632, Cell Signaling, Beverly, MA); 1: 500 Thr231 (710126,
Thermo Scientific); 1: 1000 GAPDH (Sigma-Aldrich). Membranes were washed with
TBST 3 times and then incubated with the respective anti-mouse or anti-rabbit IRDye
680 (Li-Cor, Lincoln, NE) at dilution 1: 5,000- 10,000 for 1 h at room temperature.
After washing the membranes with TBST 3 times and TBS 2 times, images were taken
with Odyssey Infrared Imaging System (Li-Cor). Membranes were reprobed for
GAPDH to obtain protein/GAPDH ratio. The intensities of the Western blot bands
were obtained using Odyssey V1.2 Software (Li-Cor).

RNA isolation, cDNA synthesis, and quantitative real-time PCR
RNA was isolated from cortical tissue following the TRIzol Reagent method
(Invitrogen), checked for integrity using NanoDrop 2000 Micro-Volume UV-Vis
Spectrophotometer (Thermo Scientific) and reverse transcribed to cDNA using iScript
Select cDNA Synthesis Kit using the manufacturer's instructions (Bio-Rad). About
1000 ng of RNA was diluted to 20 µl with nuclease-free water, 4 µl 5x iScript select
reaction mix, and 1 µl of reverse transcriptase added. Samples were incubated at 42 oC
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for 90 min and then at 85 oC for 5 min to terminate the reaction. All incubations were
conducted using MJ Research MiniCycler PTC- 150 (Bio-Rad). Primer pairs for
human tau and GAPDH were obtained from Invitrogen as follows: tau (exon 2- 3)
sense 5'-TGAACCAGGATGGCTGAGC-3' and antisense 5'TTGTCATCGCTTCCAGTCCRT-3' and GAPDH sense 5'AGGTCGGTGTGAACGGATTTG-3' and antisense 5'TGTAGACCATGTAGTTGAGGTCA-3'. Each real-time PCR reaction mix contained
1 µl cDNA, 0.5 µl of each sense and antisense primer, 4.25 µl nuclease-free water, and
6.25 µl SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA)
following the standard protocol: 50 oC for 2 min followed by 95 oC for 10 min then 40
cycles of 95 oC for 15 sec and 60 oC for 1 min. The reaction was performed and
analyzed using ViiA7 RUO Software (Applied Biosystems) and expression data were
reported relative to GAPDH mRNA using the 2-∆∆Ct method.

Perfusion Preparation and Immunohistochemistry
After 34 days of TA treatment, htau mice (aged 13 months) were prepared for
immunohistochemistry on Day 35. Mice were deeply anesthetized with an
intraperitoneal injection of 0.1 ml/10 g of xylazine- ketamine mixture (100 mg/ml- 10
mg/ml) and perfused transcardially with 100 ml of perfusion wash consisting of 0.8%
sodium chloride, 0.8% sucrose, 0.4% dextrose, 0.034% anhydrous sodium cacodylate,
and 0.023% calcium chloride. After that, mice were perfused with 100 ml of perfusion
fix that consisted of 4% paraformaldehyde, 4% sucrose, and 1.07% anhydrous sodium
cacodylate (pH 7.2- 7.4), and their brains were removed. The extracted brains were
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post-fixed in the perfusion fix solution overnight and then they were cryopreserved in
30% sucrose solution. Fixed brains were sent to NeuroScience Associates (Knoxville,
TN) for staining and coronal sectioning for p-tau Thr231 at a dilution of 1: 2,500. The
frontal cortex and striatum were sectioned and the cell bodies and apical dendrites and
axon tracts were stained, respectively.

Statistical Analysis
Data were represented as the mean + standard error of the mean (SEM).
Assessment of performance in MWM daily training sessions was determined using
one-way ANOVA with Tukey-Kramer multiple comparison post-test, using GraphPad
InStat 3 software (GraphPad Software, La Jolla, CA). Statistical analysis of western
blot bands was determined by one-way ANOVA and Holm- Sidak comparisons with
SigmaStat 3.5 software (Systat Software, Inc., San Jose, CA). Results with a p-value
of <0.05 were considered statistically significant and were marked with asterisks
accordingly.
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CHAPTER 3
RESULTS
Body weight was monitored during the study with no significant change and
no overt toxic effects of TA administration were observed when compared to the nontreated mice (Table 1). Standard PCR determined which mice contained the human tau
transgene (Fig. 3). The presence of a band distinguished which mice were carriers of
the human tau gene and which mice were non-carriers of the gene. In addition,
Western blot confirmed that the carriers contained the human tau gene, shown by ptau Ser396, while the non-carriers were absent of the band (Fig. 4). GAPDH was reprobed on the same membrane to confirm the presence of the protein. The effects of
TA on tau are reported below.

Evaluation of cognitive function in htau mice
Visuospatial and learning memories were assessed by the MWM in animals
aged 3-4 months. To ensure carrier mice of the human tau gene were an appropriate
control group with impaired memory at this age, they were compared to the noncarrier htau mice. After the second day of training, the control carriers exhibited
slower learning when compared to the control non-carrier group (Fig. 5). After Day 2,
the non-carriers consistently had faster escape latencies between the two control
groups.

Administration of tolfenamic acid restores cognitive function in htau mice
It was previously shown that mice in the control carrier group have impaired
cognitive function and memory deficit in the MWM. To further study if TA improves

13

the memory deficits in the behavior study, 5 and 50 mg/kg TA was administered to
animals (aged 3-4 months). Over the training course of 8 days, both the memory in the
5 and 50 mg/kg TA were attenuated with drug treatment when compared to the control
group (Fig. 6). Both TA treatment groups had improved learning acquisition with
faster escape latencies than the control carrier. The 5 mg/kg TA group had the fastest
escape latency between the groups and learning memory was significantly improved in
Days 3, 4, and 7, measured by one-way ANOVA (p < 0.05). In addition, probe trials,
which assessed the percent time spent in the correct quadrant containing the hidden
platform, demonstrated that the control carriers had learning deficits compared to the
control non- carrier, 5 and 50 mg/kg TA in both Day 24 and Day 34 (Fig. 7). This
further illustrated that not only do the non-carriers retain the long-term memory of the
platform's location, but that animals dosed with TA recovered their cognitive function
as shown by significantly spending more time in the correct quadrant with the hidden
platform measured by one-way ANOVA (p < 0.05).

Tolfenamic acid decreases tau protein levels and gene expression
Following 34 days of TA administration, total tau protein levels were
significantly decreased in both the 5 and 50 mg/kg TA treated groups when compared
to the control carriers as measured by Western blot (Fig. 8a). Tau protein levels were
quantified as a ratio to housekeeping protein GAPDH (Fig. 8b). Statistics was
determined by one-way ANOVA (p = 0.032) and significance by Holm- Sidak posttest (p < 0.05). In addition, tau gene expression was lowered with TA treatment. Tau
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mRNA were reduced by 12% and 23% in the 5 and 50 mg/kg, respectively, compared
to the control carriers (Fig. 9).

Phosphorylated tau is lowered with tolfenamic acid treatment
Hyperphosphorylated tau loses its ability to bind and stabilize microtubules so
levels of p-tau were examined with TA. p-tau Ser396 protein levels were lowered in
both 5 and 50 mg/kg TA groups analyzed by Western blot (Fig. 10a). Band intensities
were measured (Fig. 10b). Protein levels of p-tau Thr231 were also reduced after
dosing with TA. Thr231 levels were decreased with drug treatment measured by
Western blot (Fig. 11a). Thr231 protein was quantified with GAPDH levels and was
reduced (Fig. 11b) as determined by one-way ANOVA (p = 0.007) with Holm- Sidak
post-test (p < 0.05).

Immunohistochemistry
As previously described, htau mice begin aggregating hyperphosphorylated tau
at 3 months of age. After treating mice with 0, 5, and 50 mg/kg TA, mice (aged 13
months) brains were sectioned and stained for p-tau Thr231 (Fig. 12; 5 mg/kg TA not
shown). The frontal cortex showed decreased Thr231 staining in the cell bodies and
dendrites with the TA treatment compared to the control group. Dosing with TA also
reduced the Thr231 intensity staining of the axon tracts in the striatum.
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CHAPTER 4
DISCUSSION
TA is a novel drug for AD treatment. It has been used for the management of
migraines and rheumatoid arthritis for over 35 years in Europe. This makes TA a wellestablished and promising drug for repurposing in AD. Although the antiinflammatory benefits of NSAIDs have been studied in AD (Weggan et al., 2001;
Wilkinson et al., 2012), it is TA's unique mechanism to chelate Sp1 that makes it an
outstanding candidate for drug development in AD (Abdelrahim et al., 2006; Adwan
et al., 2011; unpublished data). Many cancer studies have reported TA inhibition of
Sp1 (Basha et al., 2006, 2011; Colon et al., 2011; Eslin et al., 2013; Maliakal et al.,
2012; Sankpal et al., 2012; Sutphin et al., 2014). Sp1 was shown to be elevated in the
frontal cortex of AD brains and in the brains of AD mouse models (Citron et al., 2008;
Santpere et al., 2006). Targeting this transcription factor is not likely to produce
detrimental effects because Sp1 binds to CG-rich promoter regions which are present
in <10% of genes (Levotsky and Dynan, 1989). In addition, Sp1 is essential during
early embryonic development but not necessary for cell growth and differentiation
later in life (Marin et al., 1997). Although TA can affect both APP and tau through
Sp1, other studies suggest targeting tau may be more effective than the APP pathway.
The amyloid hypothesis has driven the development of many drugs that target
the Aβ pathway and thus far, no drug has been successfully approved. For example,
the hopeful anti-amyloid immunotherapy drugs, which use antibodies against Aβ (e.g.
bapineuzumab and solanezumab) made it to Phase 3 clinical trials. However both
drugs failed in that stage, showing no significant difference between the treatment
16

groups and control (Salloway et al., 2014). Semagacestat, a drug that inhibits the
cleaving process of APP, has also failed in Phase 3. Moreover, 65.6% of drugs
targeting the Aβ pathway from 2002- 2012 have failed, showing no efficacy against
this target (Cummings et al., 2014). As a result, we have shifted our focus on tau since
it is more associated with cognitive failure than Aβ (Medina, 2011; Terry et al., 1964;
Thal et al., 2004). Reducing tau and Aβ levels did improve cognition in mouse models
that express tangles and plaques; however, lowering Aβ alone did not improve
cognitive function (Iqbal et al., 2009). Additionally, AD is the most common
tauopathy and by focusing on tau, it may help treat other diseases.
Tauopathies are a class of over 20 neurodegenerative diseases characterized by
hyperphosphorylated tau and impaired memory with no known cure (Brunden et al.,
2009; Lee et al., 2001; Santpere et al., 2006). Here, tau and cognitive deficits exist
without the presence of Aβ (Iqbal et al., 2010). In fact, tau pathology is more
corrolated with dementia in humans than β- amyloidosis (Terry et al., 1964; Thal et
al., 2004). By targeting tau and the cognitive deficits associated with it, TA could be
effective in such tauopathies like frontotemporal dementia and parkinsonism linked to
chromosome 17 (FTDP-17), progressive supranuclear palsy, and Pick's disease.
TA's distinct mechanism of action is a promising, upstream intervention that is
able to target tau and other AD pathological features. Furthermore, we have previously
shown that administering TA in mice lowers Sp1 levels, reducing the subsequent AD
biomarkers such as APP, Aβ, BACE1, CDK5, p-tau Ser235 and Thr181 (Adwan et al.,
2011, 2014; Subaeia 2013, 2015). p-tau Thr231 and Ser396 are almost fully
phosphorylated in PHF tau (Morishima- Kawashima et al., 1995). In addition, Thr231
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phosphorylation inhibits tau's microtubule-binding capability by 26% (Sengupta et al.,
1998). TA has the ability to decrease tau and its phosphorylated state as shown in
Figure 8, 10, and 11. In the MWM, the low dose of 5 mg/kg TA showed better
improvement in learning and memory compared to the 50 mg/kg TA. This reflects the
human equivalent dose more accurately, where it is recommended to take a dose of
200 mg, up to 3 times a day, during a migraine attack (EMEA, 1997).
We have proposed a novel drug that can not only recover cognitive function in
mice that contain the human tau gene, but also demonstrated that tau can be reduced in
older mice with tau aggregation. The current AD drugs are not disease- modifying, as
they only mask the symptoms and the memory is not attenuated. TA has the potential
to treat AD by targeting crucial biomarkers involved in this neurodegenerative disease.
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Figure 1. Proposed mechanism of tolfenamic acid
(TA) acting on transcription factor Sp1. TA prevents
Sp1 from binding to the promoter region of the tau
gene, reducing the amount of tau protein and potential
NFT, resulting in lower AD pathology.
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Figure 2. Timeline of dosing mice daily with TA for 34 days. Morris water
maze (MWM) started on day 15 and continued for eight consecutive days.
Following MWM conclusion, Probe Trial I was performed on Day 24 and
Probe Trial II on Day 34, to assess long-term memory retention. Mice were
sacrificed on Day 35 and tissues were collected.

20

Figure 3. Genotyping of htau mice analyzed by
standard PCR. Bands represents human tau
transgene while blank lanes represent mice
without the human tau gene.
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Figure 4. The presence or absence of the
human tau gene in htau mice analyzed
by Western blot. Using p-tau Ser396specific antibodies, cortical p-tau Ser396
was not found in non-carrier (NC) mice
and while carrier (C) mice had Ser396
protein present. Housekeeping protein
GAPDH was re- probed on the same
membrane.
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Figure 5. Impaired memory in the carrier animals were seen when compared to
the non-carrier group in the Morris water maze. Learning deficits were seen in
the carriers at Day 2 of training and continued to have a longer escape latency
compared to the non-carrier. Statistics were analyzed by one way ANOVA
with Tukey- Kramer post hoc test (p < 0.05), control non-carrier n= 10, control
carrier n= 10.
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Figure 6. Administration of tolfenamic acid attenuates memory observed in
the Morris water maze. "*" indicates significantly different from control,
determined by one-way analysis of variance with Tukey- Kramer post hoc test
to compare all the columns (*p < 0.05, **p < 0.01), obtained using GraphPad
Instat 3 software. Control n= 10, 5 mg/kg = 9, 50 mg/kg = 10.
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Figure 7. Long-term memory assessment of htau mice in probe
trials after dosing with tolfenamic acid. The time spent in
correct quadrant after acquisition trial- training trials was
measured (A) Probe Trial I (Day 24). (B) Probe Trial II (Day
34). "*" indicates significantly different from the other groups
measured by one way ANOVA with Tukey- Kramer post hoc
test (p < 0.05) using GraphPad InStat3 software. Control noncarrier n= 10, control carrier n= 10, 5 mg/kg = 9, 50 mg/kg =
10.
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Figure 8. Cortical tau levels after administration of
tolfenamic acid. (A) Total tau protein levels measured
by Western blot. (B) Quantitative total tau protein levels
normalized to GAPDH levels. Values shown are for the
mean + SEM, n= 4. "*" indicates significantly lower
than the control determined by one way ANOVA (p =
0.032) and p < 0.05 according to Holm- Sidak post-test.
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Figure 9. Tau gene expression decreased with tolfenamic
acid administration. Tau mRNA was measured in cortical
tissue by real-time PCR (qPCR) with GAPDH as endogenous
control. Values are shown as +SEM, control n= 4; 5 mg/kg
TA n= 5; 50 mg/kg TA n= 5.
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Figure 10. Levels of phosphorylated tau at Ser396 after
dosing with tolfenamic acid. (A) p-tau Ser396 protein
represented by Western blot. (B) Protein levels were
quantified as protein-to-ratio of housekeeper GAPDH.
Values shown are for the mean + SEM, n=4).
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Figure 11. Phosphorylated levels of tau at site Thr231
after tolfenamic acid administration. (A) p-tau Thr231
protein levels determined by Western blot analysis. (B)
Protein quantification was normalized to GAPDH protein
levels. Values are shown for the mean + SEM, n= 4). "*"
denotes statistically different from control measured by
one-way ANOVA (p = 0.07) and p < 0.05 according to
Holm- Sidak post-test.
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Figure 12. Phosphorylated tau staining was reduced following
treatment with tolfenamic acid. Cell bodies, dendrites and axonal
tracts in the frontal cortex and striatum were stained for p-tau Thr231
in the control and 50 mg/kg tolfenamic acid group.
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Table 1. Average weight of each treatment group
over administration of either control corn oil or
tolfenamic acid showed no serious change in
weight or toxic effects of tolfenamic acid during
the 34 days of dosing, followed by sacrifice on
Day 35.
Groups
Control Carrier
Control Non-carrier
5 mg/kg TA
50 mg/kg TA

Day 1 (g)
36.58
30.73
33.99
34.75

Day 35 (g)
34.90
30.39
33.26
33.97
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